Oncology
Excerpt from the Press Release: SHENZHEN, China and BOSTON, Oct. 27, 2021 /PRNewswire/ — Signet Therapeutics and XtalPi Inc., a physics-based, AI-powered drug R&D company, announced the expansion of their AI drug discovery collaboration to include a new first-in-class program against a novel cancer target identified by Signet. The two companies entered into a strategic collaboration in 2020 and…
Read More
Excerpt from the Press Release: NEEDHAM, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that data on patient-reported tolerability assessment of intraprostatic injections will be presented in a virtual poster session at the 28th Annual Prostate Cancer Foundation Scientific Retreat. Date: Thursday, October 28, 2021 Presenter: Laura K. Aguilar, MD, PhD, Chief Medical Officer at…
Read More
Excerpt from the Press Release: MENLO PARK, Calif.–(BUSINESS WIRE)–Synthekine Inc., an engineered cytokine therapeutics company, today announced it is advancing its IL-2 partial agonist, STK-012, into clinical investigation following clearance of its investigational new drug (IND) application by the U.S. Food and Drug Administration (FDA). Synthekine will evaluate STK-012 in a Phase 1a/1b, open-label, multi-center,…
Read More
Excerpt from the Press Release: SAN DIEGO, Oct. 28, 2021 /PRNewswire/ — HUYABIO International (HUYABIO™), the leader in accelerating global development of China’s pharmaceutical innovations, announced today the FDA clearance of HBI-2376 as an Investigational New Drug, or IND, for a Phase 1 study. The authorization to proceed enables the first testing in patients for whom…
Read More
Excerpt from the Press Release: FOSTER CITY, Calif.–(BUSINESS WIRE)–Oct. 28, 2021– Gilead Sciences, Inc. (Nasdaq: GILD) today announced it has entered into a clinical trial collaboration and supply agreement with Merck (known as MSD outside of the United States and Canada) to evaluate the efficacy of Gilead’s Trop-2 targeting antibody-drug conjugate Trodelvy® (sacituzumab govitecan-hziy) in…
Read More
– The new agreements mean BridgeBio has collaborations with 25 leading academic institutions focused on genetic disease and precision oncology Excerpt from the Press Release: PALO ALTO, Calif., Oct. 29, 2021 /PRNewswire/ — BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced two new academic collaborations with Columbia University…
Read More
Second study of evorpacept in patients with myeloid malignancies Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the first patient has been dosed in the Phase…
Read More
Excerpt from the Press Release: SAN MATEO, Calif. and MUMBAI, India, Oct. 21, 2021 /PRNewswire/ — Rakuten Medical Inc, and Karkinos Healthcare Private Limited announced a strategic collaboration to expand the reach of novel cancer care to India. This includes a minority stake acquisition in Karkinos Healthcare by Rakuten Medical. Rakuten Medical’s investment marks Karkinos Healthcare’s first international investor. Rakuten…
Read More
Intra-articular (IA) Delivery of AMB-05X Demonstrates Proof-of-Concept in TGCT With A Rapid Onset of Tumor Reduction in All Patients Within Six Weeks Interim AMB-05X Data Support Potential for Best-in-Class Therapy for Treatment of TGCT Excerpt from the Press Release: REDWOOD CITY, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) — AmMax Bio, Inc. (“AmMax”), a private clinical-stage…
Read More
“Pre-IPO” Biotech Startup Kills Advanced Stage Breast Cancers; Accepts Global Crowdfunding Investors
Excerpt from the Press Release: SAN FRANCISCO, Oct. 14, 2021 /PRNewswire/ — In recognition of Breast Cancer Awareness Month, DeoBioSciences, Inc. (“DBS”), a minority/female founded, preclinical stage, biotech company, is highlighting its impressive research results against several types of treatment-resistant breast cancer. DeoBioSciences’ drug candidate, DBX-31, can selectively target and kill a wide range of tough, treatment-resistant, advanced…
Read More